Clinical trials: Active Control
Pulmonary Disease, Chronic Obstructive
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD.
- Trial name
- ACTIVATE (NCT02424344)
- Testing
- Aclidinium/Formoterol
- Where
- 26 sites in Canada, Germany and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs.
- Trial name
- NCT01617005
- Testing
- Tocilizumab
- Where
- Montenegro
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Pain Associated With Fibromyalgia
Treatment of Pain Associated With Fibromyalgia
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.
- Trial name
- NCT02187159
- Testing
- DS-5565, Pregabalin
- Where
- 176 sites in United States, Australia and 10 more
- Volunteers
- 1,270 people
- Sponsor
- Daiichi Sankyo
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Sleep Deprivation
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.
- Trial name
- NCT01096680
- Testing
- SPD489 20 mg, SPD489 50 mg, SPD489 70 mg
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Shire
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Prostate Adenocarcinoma
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT02721979
- Testing
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Bunionectomy, Hallux Valgus
Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
The study is conducted sequentially in two parts. Part A: The purpose is to obtain information on pharmacokinetic (PK) profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg…
- Trial name
- NCT05157841
- Testing
- Bupivacaine liposome injectable suspension 266 mg, Bupivacaine HCl, Bupivacaine liposome injectable suspension 133 mg
- Where
- 7 sites in United States
- Volunteers
- 185 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Postherpetic Neuralgia
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
The primary purpose of this study is to evaluate the analgesic efficacy of ADL5747 in participants with postherpetic neuralgia (PHN).
- Trial name
- NCT01058642
- Testing
- ADL5747, Pregabalin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacterial Infections, Virus Diseases
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.
- Trial name
- NCT01340937
- Testing
- V419, PENTACEL™, Prevnar 13™
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
Effect of Indacaterol on Inspiratory Capacity (IC)
This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive…
- Trial name
- NCT01012765
- Testing
- Indacaterol, Tiotropium
- Where
- 21 sites in Germany
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of subcutaneous injections (under the skin) of golimumab for the treatment of active ankylosing spondylitis [AS(arthritis of the spine)].
- Trial name
- NCT00265083
- Testing
- golimumab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 356 people
- Sponsor
- Centocor, Inc.
Diffuse Large B-cell Lymphoma
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment.
- Trial name
- ECHELON-3 (NCT04404283)
- Testing
- Brentuximab vedotin, Rituximab, Lenalidomide
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 240 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lymphocytic Colitis, Diarrhea
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy.
- Trial name
- NCT00217022
- Testing
- Budesonide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Acanthamoeba Keratitis
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Prospective randomized study to evaluate the efficacy, safety and tolerability of 0.08% polihexanide (PHMB) eye drops in patients affected by acanthamoeba keratitis.
- Trial name
- NCT03274895
- Testing
- PHMB 0.08%, Propamidine 0.1%, PHMB 0.02%
- Where
- 6 sites in Italy, Poland and 1 more
- Volunteers
- 135 people
- Sponsor
- SIFI SpA
Ulcerative Colitis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
- Trial name
- SEA TURTLE (NCT04577794)
- Testing
- GLPG3970
- Where
- 15 sites in Georgia, Moldova and 2 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- VOYAGE 1 (NCT02207231)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 97 sites in United States, Australia and 8 more
- Volunteers
- 837 people
- Sponsor
- Janssen Research & Development, LLC